retatrutide clinical trial results obesity Lilly orforglipron oral GLP-1 phase 3 weight loss Eli Lilly Obesity Drug Market

Realistic expectations on weight change over six to twelve months

The Wegovy labeling directs clinicians to "monitor renal function in patients reporting adverse reactions to WEGOVY that could lead to volume depletion, especially during dosage initiation and escalation." Volume depletion from persistent gastrointestinal losses can precipitate acute kidney injury, and that risk is higher in people with existing kidney impairment or on medications that affect renal perfusion

Unfortunately, we have no follow-up information from those patients to assess whether study participants maintained their weight loss after stopping the medication

GHK-Cu is often discussed in longevity research because it connects to several key areas of skin health: * Cellular repair support * Structural support (collagen and elastin) * Regeneration pathways * Skin resilience as we age As natural levels decline over time, maintaining supportive routines becomes increasingly important